GlassScriptPhysician profile
Bijal A Katarki
NPI 1669583910
$6,829.15
in general payments reported to CMS, 2019-2025
35 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $696 · 2021: $1,366 · 2022: $738 · 2023: $1,413 · 2024: $987 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.69 |
| Education | $155.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,555.46 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,104.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $634.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $441.63 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astellas Pharma US INC | $412.33 | 2021-2025 | Veozah |
| Pfizer INC. | $402.17 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.80 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $316.09 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $225.43 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $155.70 | 2020-2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $131.81 | 2019-2023 | Dificid |
| Allergan, INC. | $130.04 | 2019-2020 | |
| Exact Sciences Corporation | $109.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $104.68 | 2023-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $103.19 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $102.85 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $65.38 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $51.70 | 2024-2025 | Rexulti |
| Inspire Medical Systems, INC. | $34.00 | 2025 | Inspire |
| Genentech USA, INC. | $33.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.73 | 2024 | |
| Mayne Pharma Commercial LLC | $32.22 | 2025 | |
| Abbott Laboratories | $31.70 | 2023-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $29.42 | 2021 | |
| Daiichi Sankyo INC. | $29.40 | 2025 | Injectafer |
| Becton, Dickinson and Company | $25.73 | 2024 | Bd Max System, Bd Max Instrument |
| Mylan Specialty L.P. | $20.60 | 2020 | |
| Exeltis, USA INC. | $20.38 | 2022 | |
| Agios Pharmaceuticals, INC. | $19.83 | 2025 | Pyrukynd |
| Sunovion Pharmaceuticals INC. | $19.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.51 | 2025 | |
| Linus Health, INC. | $14.54 | 2023 | |
| Seqirus USA INC | $14.48 | 2025 | Flucelvax, Fluad |
| Currax Pharmaceuticals LLC | $14.36 | 2024 | Contrave |
| Shire North American Group INC | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijal Katarki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.